Johnson & Johnson’s nipocalimab-aa4hu, marketed as IMAAVY, has been approved by the U.S. Food and Drug Administration for generalized myasthenia gravis (gMG), according to a press release published Wednesday.
Niopocalimab is also being studied in fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare but serious disorder caused by harmful maternal antibodies.
Nipocalimab works by blocking the neonatal FcRn, a key protein that prevents immunoglobulin G (IgG) antibodies — including dangerous autoantibodies — from being broken down. By lowering levels of IgG, it addresses a root cause of several autoantibody diseases. In FNAIT, these maternal antibodies attack fetal platelets, causing internal bleeding and, in severe cases, fetal death. No approved treatment currently exists for FNAIT, making nipocalimab’s mechanism especially promising for affected families. HDFN follows a similar process, with maternal antibodies targeting fetal red blood cells.
“Today’s announcement provides another option which could help address the constant uncertainty and heavy physical and mental toll that MG symptom relapse presents to patients and their families.”
In the Vivacity-MG3 trial for gMG, nipocalimab delivered rapid and sustained symptom relief and control, with improvements lasting up to 20 months in an ongoing extension study. These results underscore the drug’s potential to offer long-lasting benefits in other IgG-mediated conditions like FNAIT, where durable antibody suppression could prevent life-threatening complications before birth.
Read more about FNAIT treatment and care
The approval covers both anti-acetylcholine receptor and anti-muscle-specific kinase antibody positive patients, who make up over 90% of the gMG population. Adolescents aged 12 to 17 also showed strong responses in a separate pediatric trial, further supporting its safety and effectiveness across age groups.
Beyond its therapeutic action, nipocalimab is designed to preserve other immune system functions — a key feature for both pregnant patients and newborns, where broad immunosuppression would be unsafe. This precision makes it especially well-suited for future use in FNAIT.
Johnson & Johnson has begun global regulatory submissions for nipocalimab in gMG and continues trials in pregnancy-related conditions. Its FDA approval now marks a major step toward new hope for families facing serious, antibody-driven diseases with few or no current treatment options.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
